Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | HCK | P08631 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.43 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22430997 | 0.85 | ALDH1A1 (0.61) | ALDH1A1CYP3A4HSD17B10TSHRTDP1 | |
| SCHEMBL31304141 | 0.83 | AOC3 (0.40) | ALDH1A1CYP3A4HSD17B10TSHRTDP1 | |
| SCHEMBL29133002 | 0.82 | ABCB1 (0.39) | ALDH1A1CYP3A4HSD17B10TSHRAOC3 | |
| SCHEMBL24557270 | 0.79 | LMNA (0.39) | ALDH1A1PIK3CDABL1EGFRHCK | |
| SCHEMBL30964050 | 0.76 | RAB9A (0.41) | ALDH1A1CYP3A4HSD17B10TSHRTDP1 | |
| SCHEMBL30184489 | 0.76 | CHEK1 (0.46) | ALDH1A1TDP1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL29212300 | 0.76 | CHEK1 (0.46) | ALDH1A1TDP1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL15652281 | 0.76 | ALDH1A1 (0.56) | ALDH1A1CYP3A4HSD17B10TSHRTDP1 | |
| SCHEMBL22130201 | 0.76 | ALDH1A1 (0.66) | ALDH1A1CYP3A4HSD17B10TSHRTDP1 | |
| SCHEMBL17049238 | 0.75 | ALDH1A1 (0.59) | ALDH1A1CYP3A4HSD17B10TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| EP-3915986-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Voronoi Inc. (KR) | 2021-12-01 | — | — | EP | disclosed |
| EP-3915986-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Voronoi Inc. (KR) | 2021-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TTK, TTBK1, TTBK2 | ALDH1A1 3055/4885CYP3A4 1966/4885HSD17B10 967/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | ALDH1A1 2527/4885CYP3A4 4371/4885HSD17B10 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.